Crohn's Disease News and Research

Latest Crohn's Disease News and Research

HRF inhibitors may provide new therapeutic avenue for treatment of asthma and allergies

La Jolla Institute for Allergy & Immunology scientists have identified the histamine releasing factor (HRF) molecule as a promising target for developing new treatments for a number of allergic reactions including asthma.

3 Dec 2011

La Jolla researchers create first cellular movies showing destruction underlying type 1 diabetes

A war is being waged in the pancreases of millions of people throughout the world. The siege leads to the development of type 1 diabetes and has been a battlefield largely hidden from view-- until now.

3 Dec 2011

Study identifies sulfomucins as potential targets for therapies to treat chronic intestinal inflammatory disorders

In a paper published in the December 2011 issue of Experimental Biology and Medicine, a team of scientists at the University of Illinois, Urbana-Champaign led by Rex Gaskins, PhD have demonstrated that both microbial and host inflammatory factors modulate sulfomucin production in a human cell line, LS174T, that models intestinal goblet cells.

3 Dec 2011

Oral ingestion of apple polyphenols can prevent colitis in mice

Here's another reason why "an apple a day keeps the doctor away"-according to new research findings published in the Journal of Leukocyte Biology, oral ingestion of apple polyphenols can suppress T cell activation to prevent colitis in mice.

1 Dec 2011

DFG approves establishment of new research training groups

To further enhance the promotion of early-career researchers in Germany, the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) has approved the establishment of 16 new Research Training Groups. This decision was made by the DFG's relevant Grants Committee in Bonn.

29 Nov 2011

CIC microGUNE and Biodonostia test a new technique for evaluating intestinal diseases in patients

The CIC microGUNE research centre and the Biodonostia Institute have recently started testing a new technique for assessing the severity of inflammatory intestinal diseases, such as Crohn's Disease, in patients at the Donostia Hospital.

23 Nov 2011

Certain IBD patients at increased risk of skin cancer

Certain patients with inflammatory bowel disease (IBD) may have an increased risk of skin cancer, which is intensified by the use of immunosuppressant medications , according to two new studies in Gastroenterology, the official journal of the American Gastroenterological Association. Immunosuppressants are commonly used in the treatment of IBD.

21 Nov 2011

SHARPIN protein regulates human cell activity

The research teams headed by Prof. Johanna Ivaska (University of Turku and VTT Technical Research Centre of Finland) and Prof. Marko Salmi (University of Turku and the National Institute for Health and Welfare) have discovered that the SHARPIN protein regulates human cell activity.

17 Nov 2011

Soligenix third quarter revenues increase to $5,796,000

Soligenix, Inc., a development stage biopharmaceutical company, announced today its financial results for the third quarter of 2011.

14 Nov 2011

Positive results from ChemoCentryx CCX354 Phase II study on RA

ChemoCentryx, Inc., today announced that it reported positive Phase II results for CCX354 at the Annual Meeting of the American College of Rheumatology.

9 Nov 2011

UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting

UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, is proud to sponsor several key sets of Cimzia (certolizumab pegol) data at the American College of Rheumatology's 2011 Annual Scientific Meeting in Chicago, November 5-9.

7 Nov 2011

SCRIP honors Glenmark for business excellence and innovative R & D capabilities

SCRIP, a leading global pharmaceutical and biotech news publication, honoured Glenmark with two global recognitions, for its business excellence and innovative R & D capabilities.

5 Nov 2011

Potential role for UV light exposure, vitamin D levels in chronic digestive conditions

New research points to a potential role for UV light exposure and vitamin D levels in chronic digestive conditions.

1 Nov 2011

NPS announces new data from GATTEX Phase 3 study on short bowel syndrome

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced new data from STEPS 2, a long-term open-label study, showing that GATTEX (teduglutide) was associated with achieving and maintaining clinically meaningful reductions in parenteral nutrition (PN) and intravenous (IV) fluid volume in adult subjects with short bowel syndrome.

1 Nov 2011

UCB to present new data on Cimzia at ACG annual scientific meeting

UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, will present new data on Cimzia at the American College of Gastroenterology (ACG) Annual Scientific Meeting, taking place in Washington D.C. from October 28 to November 2.

1 Nov 2011

UV light exposure and vitamin D play a potential role in chronic digestive conditions

New research points to a potential role for UV light exposure and vitamin D levels in chronic digestive conditions; Crohn's disease, a serious inflammatory condition in the small intestine; and ulcerative colitis (UC), which similarly affects the colon.

31 Oct 2011

GC-C agonists have potential to delay progression of colitis into colon cancer

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that poster P409 presented at the upcoming 2011 annual scientific meeting of the American College of Gastroenterology highlights the potential use of guanylate cyclase-C agonists to delay progression of colitis into colon cancer.

31 Oct 2011

Beneficial intestinal bacteria can activate immune cells and trigger MS

Multiple sclerosis is caused by a combination of genetic and environmental factors. For a long time, pathogens were believed to be such external influences. According to scientists from the Max Planck Institute of Neurobiology in Martinsried, however, it is apparently not harmful bacteria that trigger multiple sclerosis, but beneficial ones - specifically, the natural intestinal flora, which every human being needs for digestion.

28 Oct 2011

La Jolla Institute becomes 5th participant in novel stem cell research collaboration

The La Jolla Institute for Allergy & Immunology has become the fifth organization in the prestigious Sanford Consortium for Regenerative Medicine, joining colleagues from the Salk Institute for Biological Studies, The Scripps Research Institute, University of California, San Diego and the Sanford-Burnham Medical Research Institute in the first-of-its-kind multi-institutional stem cell research collaboration.

28 Oct 2011

Study provides details on genetics behind many metabolic diseases

In what is so far the largest investigation of its kind, researchers uncovered a wide range of new insights about common diseases and how they are affected by differences between two persons' genes. The results from this study could lead to highly targeted, individualized therapies.

27 Oct 2011